
Eldecalcitol reduces risk of vertebral fractures in osteoporotic patients

Eldecalcitol reduces risk of vertebral fractures in osteoporotic patients
A new active vitamin D3 analog, eldecalcitol, prevents the risk of osteoporotic fractures--a randomized, active comparator, double-blind study
Bone. 2011 Oct;49(4):605-12. doi: 10.1016/j.bone.2011.07.011. Epub 2011 Jul 19Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
Synopsis
1087 patients were randomized to determine the difference between two vitamin D analogs on the reduction of vertebral fractures in osteoporotic patients. Enrolled patients were allocated to receive eldecalcitol or alfacalcidol once daily, and were followed for 3 years. The results indicated that eldecalcitol reduced the risk of vertebral and wrist fractures, improved lumbar spine and total hip bon...
To view the full content, login to your account,
or start your 30-day FREE Trial today.
FREE TRIAL
LOGIN
Forgot Password?
Explore some of our unlocked ACE Reports below!

Learn about our AI Driven
High Impact Search Feature

Our AI driven High Impact metric calculates the impact an article will have by considering both the publishing journal and the content of the article itself. Built using the latest advances in natural language processing, OE High Impact predicts an article’s future number of citations better than impact factor alone.
Continue
Join the Conversation
Please Login or Join to leave comments.